🚀 VC round data is live in beta, check it out!
Procaps Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Procaps Group and similar public comparables like Pentixapharm Holding, THX Pharma, Cue Biopharma, Oncopeptides and more.
Procaps Group Overview
About Procaps Group
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
Founded
1977
HQ
Employees
4.9K
Website
Sectors
Financials (FY)
EV
$335M
Procaps Group Financials
Procaps Group reported last fiscal year revenue of $374M and negative EBITDA of ($22M).
In the same fiscal year, Procaps Group generated $191M in gross profit, ($22M) in EBITDA losses, and had net loss of ($68M).
Revenue (LTM)
Procaps Group P&L
In the most recent fiscal year, Procaps Group reported revenue of $374M and EBITDA of ($22M).
Procaps Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $374M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $191M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 51% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($22M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (9%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($68M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (18%) | XXX | XXX | XXX |
| Net Debt | — | — | $276M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Procaps Group Stock Performance
Procaps Group has current market cap of $58M, and enterprise value of $335M.
Market Cap Evolution
Procaps Group's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $58M | 0.0% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProcaps Group Valuation Multiples
Procaps Group trades at 0.9x EV/Revenue multiple, and (15.2x) EV/EBITDA.
EV / Revenue (LTM)
Procaps Group Financial Valuation Multiples
As of April 20, 2026, Procaps Group has market cap of $58M and EV of $335M.
Equity research analysts estimate Procaps Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Procaps Group has a P/E ratio of (0.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58M | XXX | $58M | XXX | XXX | XXX |
| EV (current) | $335M | XXX | $335M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (15.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (10.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.7x | XXX | XXX | XXX |
| P/E | — | XXX | (0.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 5.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Procaps Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Procaps Group Margins & Growth Rates
Procaps Group's revenue in the last fiscal year declined by (12%).
Procaps Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Procaps Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (121%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Procaps Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Procaps Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Pentixapharm Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| THX Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cue Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncopeptides | XXX | XXX | XXX | XXX | XXX | XXX |
| Corestemchemon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Procaps Group M&A Activity
Procaps Group acquired XXX companies to date.
Last acquisition by Procaps Group was on XXXXXXXX, XXXXX. Procaps Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Procaps Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProcaps Group Investment Activity
Procaps Group invested in XXX companies to date.
Procaps Group made its latest investment on XXXXXXXX, XXXXX. Procaps Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Procaps Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Procaps Group
| When was Procaps Group founded? | Procaps Group was founded in 1977. |
| Where is Procaps Group headquartered? | Procaps Group is headquartered in United States. |
| How many employees does Procaps Group have? | As of today, Procaps Group has over 4K employees. |
| Who is the CEO of Procaps Group? | Procaps Group's CEO is Ruben Minski. |
| Is Procaps Group publicly listed? | Yes, Procaps Group is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Procaps Group? | Procaps Group trades under PROCF ticker. |
| When did Procaps Group go public? | Procaps Group went public in 2021. |
| Who are competitors of Procaps Group? | Procaps Group main competitors are Pentixapharm Holding, THX Pharma, Cue Biopharma, Oncopeptides. |
| What is the current market cap of Procaps Group? | Procaps Group's current market cap is $58M. |
| What is the current revenue of Procaps Group? | Procaps Group's last fiscal year revenue is $374M. |
| What is the current EV/Revenue multiple of Procaps Group? | Current revenue multiple of Procaps Group is 0.9x. |
| Is Procaps Group profitable? | No, Procaps Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.